Evidence map›Paper›PMID 24439527›Full record

ArticleCell calcium2014

Activity of nicotinic acid substituted nicotinic acid adenine dinucleotide phosphate (NAADP) analogs in a human cell line: difference in specificity between human and sea urchin NAADP receptors.

Ramadan A Ali, Tetyana Zhelay, Christopher J Trabbic, Timothy F Walseth, James T Slama, David R Giovannucci, Katherine A Wall

Open access · greenAbstract read
In one paragraph

Article in Cell calcium, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. NAADP-Mediated CaHandbook of experimental pharmacology · 2023
    Article
  4. NAADP-Evoked CaHandbook of experimental pharmacology · 2023
    Article
  5. NAADP Receptors.Cold Spring Harbor perspectives in biology · 2019
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ramadan A AliDepartment of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States.
Tetyana ZhelayDepartment of Neurosciences, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States.
Christopher J TrabbicDepartment of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States.
Timothy F WalsethDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, United States.
James T SlamaDepartment of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States.
David R GiovannucciDepartment of Neurosciences, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States. Electronic address: david.giovannucci@utoledo.edu.
Katherine A WallDepartment of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Sciences Campus, 3000 Arlington Avenue, Toledo, OH 43614, United States. Electronic address: katherine.wall@utoledo.edu.
University of Minnesota Medical Center · US

Funding

Chemobiologic Approach to NAADP SignalingR15GM100444 · NIGMS · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI SLAMA, JAMES T · 2012 to 2012
$351k
NIGMS NIH HHS GM100444-01NIGMS NIH HHS R15 GM100444
6 · The paper itself

Abstract

Nicotinic acid adenine dinucleotide phosphate (NAADP) is the most potent Ca2+ mobilizing second messenger that has been identified. We have previously shown that NAADP analogs substituted at the 5-position of nicotinic acid were recognized by the sea urchin receptor at low concentration, whereas the 4- substituted analogs were not as potent. However, to date the structure-activity relationship (SAR) of these analogs has not been addressed in mammalian systems. Thus, we asked whether these structurally modified analogs behave similarly in an NAADP-responsive mammalian cell line (SKBR3) using microinjection and single cell fluorescent imaging methods. Novel "caged" 4- and 5-substituted NAADP analogs that were activated inside the cell by flash photolysis resulted in Ca2+ mobilizing activity in SKBR3 cells in a concentration dependent manner, but with reduced effectiveness compared to unmodified NAADP. The SAR in mammalian SKBR3 cells was quite different from that of sea urchin and may suggest that there are differences between NAADP receptors in different species or tissues. Importantly, these data indicate that modifications at the 4- and 5-position of the nicotinic acid ring may lead to the development of functional photoaffinity labels that could be used for receptor localization and isolation in mammalian systems.

Indexed as

AnimalsCalciumCalcium SignalingCell Line, TumorFluorometryHumansNADPNiacinNicotinic AcidsOvumPhotolysisSea UrchinsStructure-Activity RelationshipUltraviolet Rays3-carboxy-1-octylcarbamoylmethylpyridiniumCalciumNAADPNADPNiacinNicotinic AcidsAntagonistsCa(2+) signalingCaged-NAADPNAADPSKBR3 cellsStructure–activity relationships

Identifiers

PMID24439527
PMCPMC4015339
OpenAlexW2054219735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.